# A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

> **NCT03645330** · — · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 1026 (actual)

## Conditions studied

- Non-small-Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03645330
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 1026 (ACTUAL)
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645330, "A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03645330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*